BRD2 and osteoporosis: There is a causal role for rising serum follicle-stimulating hormone (FSH) levels in the exaggerated Alzheimer’s disease pathophysiology during menopause, indicating an opportunity for treating Alzheimer’s disease, obesity and osteoporosis with a single agent (notably, a neutralizing anti-FSH antibody82).